# Prostatic Hyperplasia Treatment and Cancer Prevention

> **NCT03064282** · EARLY_PHASE1 · UNKNOWN · sponsor: **Manchanda Medical Clinic** · enrollment: 40 (estimated)

## Conditions studied

- Prostatic Hyperplasia

## Interventions

- **OTHER:** Placebo
- **DRUG:** papaverine

## Key facts

- **NCT ID:** NCT03064282
- **Lead sponsor:** Manchanda Medical Clinic
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-30
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-12-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03064282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03064282, "Prostatic Hyperplasia Treatment and Cancer Prevention". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03064282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*